Skip to content

Efficacy of 3D-Printed Mouth Splints

Efficacy of 3D-Printed Mouth Splints in the Management of Microstomia in Burn Patients

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06801535
Acronym
3DMS
Enrollment
10
Registered
2025-01-30
Start date
2025-02-21
Completion date
2026-12-31
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microstomia

Keywords

cleft lip and palate, craniocarpotarsal dysplasia, dental hygiene

Brief summary

The study will investigate the effectiveness of a 3D-printed mouth splint designed to increase dimensions of oral aperture and reduce disability associated with mouth contractures. The validated Mouth Impairment and Disability Assessment (MIDA) survey will be used to objectively measure patient progress in functionality and quality of life.

Detailed description

Microstomia, or reduced oral aperture, is a debilitating condition that can arise after burn injuries, particularly to the face. This condition severely impacts oral hygiene, nutrition, speech, and overall quality of life. Current management strategies often rely on therapy, surgical intervention, and splinting to improve mouth opening and functionality. However, there is a lack of accessibility to good mouth splinting devices. 3D-printed, dynamic splints offer may offer a superior and cost-effective solution that can be tailored to the patient's anatomy while allowing for at-home treatment. Sizing can also be adjusted to fit essentially any aperture since, including pediatrics. This device is intended for use at home, supported by teaching and follow-up provided by occupational therapists (OTs).

Interventions

DEVICESplint

Patients will use the splint at home 3 times daily for 10 minutes per session for 3 months total.

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Assess the impact of the 3D-printed mouth splint on oral aperture measurements over a 3-month period.

Eligibility

Sex/Gender
ALL
Age
2 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patients 2 years to 99 years of age with documented microstomia following burn injuries. * Ability to comply with prescribed home exercises and follow-up visits.

Exclusion criteria

* Cognitive or physical inability to perform the prescribed exercises. * Inability of a caretaker to be able to deliver therapy daily. * Concomitant conditions that may significantly affect oral aperture (e.g., temporomandibular joint (TMJ) disorders).

Design outcomes

Primary

MeasureTime frameDescription
Change in Oral Aperture measurementsBaseline to Month 3Difference in measurements of oral aperture from Baseline visit to Final visit will be reported - Oral aperture measurements taken with calipers

Secondary

MeasureTime frameDescription
Change in Mouth Impairment and Disability Assessment (MIDA) ScoresBaseline to Month 3The mouth impairment and disability assessment (MIDA) has a 28 item self-report portion, divided into four subscales, completed by the patient and an impairment-based section completed by the burn therapist. The Mouth Impairment and Disability Assessment (MIDA) scale typically ranges from a low score indicating minimal impairment to a high score representing significant disability, with the exact range depending on the specific version of the scale and how individual items are scored; however, most versions will have a total score that can be interpreted within a broader range of severity, with higher scores signifying greater impairment. This assessment is scored from 0 to 64. Zero is equivalent to no difficulty and 64 would indicate the highest level of difficulty.
Change in Patient Satisfaction ScoresBaseline to Month 3Total patient satisfaction scored on survey at weekly visits to be reported from 0 to 23. 0 equivalent to no satisfaction and 23 is the highest level of satisfaction.

Countries

United States

Contacts

Primary ContactStudy Coordinator
csuggs@wakehealth.edu3367164171

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026